Mucolox alone
ApprovedSmall molecule
Mucolox alone is one of 15 small molecule programs targeting Burning Mouth Syndrome. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Burning Mouth Syndrome
#DrugCompanyPhaseTrials
1Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Lexapro
AbbViePhase 3
Celexa
AbbViePhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zoloft
VViatris Specialty LLC
Phase 3
Paxil
SSebela Pharmaceuticals Development LLC
Phase 3
Western Medicine
PPeking Union Medical College Hospital
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Mucolox alone
UUniversity of Alberta
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mucolox alone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Alberta